Diridavumab
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | ? |
Source | Human |
Target | hemagglutinin |
Clinical data | |
Other names | CR6261 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6400H9934N1702O1996S48 |
Molar mass | 144196.67 g·mol−1 |
Diridavumab (CR6261) (INN[1]) is a monoclonal antibody designed for the treatment of influenza A.[2]
This drug was developed by Janssen Pharmaceutical Companies of Johnson & Johnson.
References
Categories:
- Articles with short description
- Short description is different from Wikidata
- Drugs not assigned an ATC code
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- All stub articles
- Monoclonal antibody stubs
- Experimental monoclonal antibodies